SCHEMBL26987480

SCHEMBL26987480

Cc1ccc(S(=O)(=O)N(C)c2cccc3cc[nH]c23)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ C5AR1 P21730 2/20 0.62
▸ HTT P42858 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ CA12 O43570 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ MCOLN3 Q8TDD5 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ LMNA P02545 2/20 0.48
▸ TSHR P16473 1/20 0.48
▸ C1R P00736 1/20 0.45
▸ PRSS1 P07477 1/20 0.45
▸ GAA P10253 1/20 0.45
▸ MMP2 P08253 1/20 0.43
▸ MMP9 P14780 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ NR3C1 P04150 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ NR3C2 P08235 1/20 0.42
▸ AR P10275 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6089123 0.80 NR3C1 (0.51) NPSR1L3MBTL1MAPTTSHRNR3C1
SCHEMBL7150548 0.73 C5AR1 (0.83) C5AR1HTTNPSR1L3MBTL1CA12
SCHEMBL29082200 0.72 KDM4E (0.50) NPSR1MAPTGAANR3C1PGR
SCHEMBL2367682 0.71 NR3C1 (0.64) HTTNPSR1L3MBTL1CA12CA9
SCHEMBL24125226 0.71 C5AR1 (0.77) C5AR1HTTNPSR1L3MBTL1CA12
SCHEMBL942802 0.71 C5AR1 (0.77) C5AR1HTTNPSR1L3MBTL1CA12
SCHEMBL3257725 0.71 C5AR1 (0.77) C5AR1HTTNPSR1L3MBTL1CA12
SCHEMBL6831970 0.71 C5AR1 (0.71) C5AR1HTTNPSR1L3MBTL1CA12
SCHEMBL5949287 0.70 C5AR1 (0.56) C5AR1HTTNPSR1L3MBTL1CA12
SCHEMBL944589 0.70 C5AR1 (0.75) C5AR1HTTNPSR1L3MBTL1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 — — EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 — — US disclosed
CN-119403798-A Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof 东亚ST 株式会社 2025-02-07 — — CN disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 — — US disclosed
WO-2024009215-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR C5AR1 3808/4885HTT 493/4885NPSR1 3776/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR C5AR1 3808/4885HTT 493/4885NPSR1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback